D-erythro-Sphingosine

• UNSPSC Description:

  D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator[1][2][3][4].

• Target Antigen:

  Endogenous Metabolite; Phosphatase; PKC

• Type:

  Natural Products

• Related Pathways:

  Epigenetics;Metabolic Enzyme/Protease;TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/D-erythro-Sphingosine.html

• Purity:

  98.0

• Solubility:

  DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO

• Molecular Weight:

  299.49

• References & Citations:

  [1]Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703.|[2]Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91.|[3]Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7.|[4]Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  123-78-4